Duke University

Immunolight, LLC

Glaxosmithkline LLC

Other

Smithkline Beecham (cork) Ltd

Gooden, David

Spector, Neil, L.

Xia, Wenle

Toone, Eric, J.

Walder, Harold

Beyer, Wayne, F.

Soderblom, Erik, J.

Neil Lee Spector

Harold Walder

Zakaryae Fathi

Frederic Avery Bourke, Jr

Mark Oldham

Justus Adamson

Takuya Osada

Mark DeWhirst

Paul Yoon

Kim Lyerly

Leihua Liu

David Alcorta

Wenle Xia

Wayne F Beyer

Karen Elizabeth Lackey

Wayne F Beyer, Jr

Edgar Raymond Wood, Iii

Eric John Toone

Mark W Dewhirst

David M Gooden

Robert J Mullin

Erik J Soderblom

Sydney Spector

Albert Man

Sally A Kornbluth

Manabu Kurokawa

Frederic A Bourke

Sally Kornbluth

Wayne F Bayer

A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;

X-ray psoralen activated cancer therapy (X-PACT)

A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

X-RAY psoralen activated cancer therapy (X-PACT) with associated treatments

Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

Methods of identifying and using MDM2 inhibitors

Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

Cancer treatment method

The truncated ErbB2 receptor (p95) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95inhibitor, and methods of treating such patients.

Treatment of cancers expressing p95 ErbB2

The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS6, IGF-1R and levels of apoptosis occurring in tumor tissue.

Predictive biomarkers in cancer therapy

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as pharmaceutical combinations and compositions containing the same.

The invention provides compounds of the formula (I):

Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis

Growing community of inventors

Durham, NC, United States of America

Neil Lee Spector